ProShare Advisors LLC Lowers Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

ProShare Advisors LLC decreased its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 21.5% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 57,161 shares of the biopharmaceutical company’s stock after selling 15,684 shares during the period. ProShare Advisors LLC’s holdings in Amicus Therapeutics were worth $567,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of FOLD. Headlands Technologies LLC purchased a new position in shares of Amicus Therapeutics in the 2nd quarter valued at about $89,000. Sage Capital Advisors llc acquired a new position in shares of Amicus Therapeutics during the 2nd quarter worth approximately $103,000. EntryPoint Capital LLC raised its stake in shares of Amicus Therapeutics by 278.8% during the 1st quarter. EntryPoint Capital LLC now owns 13,218 shares of the biopharmaceutical company’s stock worth $156,000 after buying an additional 9,729 shares during the period. Old Well Partners LLC purchased a new position in shares of Amicus Therapeutics during the 4th quarter valued at approximately $180,000. Finally, Mesirow Financial Investment Management Inc. acquired a new stake in Amicus Therapeutics in the 1st quarter valued at $225,000.

Wall Street Analyst Weigh In

FOLD has been the subject of a number of research analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price objective on shares of Amicus Therapeutics in a research report on Friday, September 20th. Jefferies Financial Group started coverage on shares of Amicus Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 price target on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research note on Friday, August 9th. Finally, JPMorgan Chase & Co. decreased their target price on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a research report on Friday, August 16th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $17.00.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total value of $87,825.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $10,382,718.34. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $11.71, for a total value of $87,825.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $10,382,718.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bradley L. Campbell sold 6,100 shares of Amicus Therapeutics stock in a transaction on Friday, July 5th. The shares were sold at an average price of $10.00, for a total value of $61,000.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $8,866,540. The disclosure for this sale can be found here. Insiders sold a total of 21,100 shares of company stock worth $226,375 over the last ninety days. Company insiders own 2.20% of the company’s stock.

Amicus Therapeutics Price Performance

Amicus Therapeutics stock opened at $10.71 on Monday. The company has a current ratio of 2.75, a quick ratio of 2.26 and a debt-to-equity ratio of 2.93. The company has a 50-day moving average price of $11.07 and a 200 day moving average price of $10.66. Amicus Therapeutics, Inc. has a 12-month low of $9.02 and a 12-month high of $14.57. The stock has a market cap of $3.17 billion, a P/E ratio of -21.86 and a beta of 0.69.

Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The company had revenue of $126.67 million for the quarter, compared to the consensus estimate of $121.21 million. During the same quarter in the previous year, the business earned ($0.15) earnings per share. The company’s revenue for the quarter was up 34.0% on a year-over-year basis. Sell-side analysts anticipate that Amicus Therapeutics, Inc. will post -0.08 earnings per share for the current year.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.